Access Pharma to Conduct Cobalamin siRNA Program at CNSI Symposium

ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) , a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Senior VP of R&D, David Nowotnik, Ph.D., will give two presentations today on the Company's Cobalamin siRNA program at the Novel Nanodelivery of siRNA and miRNA Symposium, hosted by the California NanoSystems Institute (CNSI) of UCLA.

Access Pharma's invited oral presentation and its poster presentation will highlight the cell targeting aspects of the Company's proprietary Cobalamin technology and the progress made by its scientist team in applying that technology to the intracellular delivery of RNAi therapeutics.

"We are delighted to have been given the opportunity to present recent data at this important meeting of leaders in the RNAi field," commented David Nowotnik, Ph.D., Access Pharma's Senior Vice President R&D. Dr. Nowotnik continued, "While RNAi therapeutics show immense promise for future treatment of a variety of diseases, their effective delivery into cells and to the nucleus of those cells remains a challenge. By using the body's natural mechanism for cellular absorption of vitamin B12, we believe that Access Pharma's Cobalamin-targeted delivery technology can play an important role in the delivery of RNAi therapeutics."


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback